Abstract
Purpose
To evaluate the cost-effectiveness of DECT versus multiphasic CT and MRI for characterizing small incidentally detected indeterminate renal lesions using a Markov Monte Carlo decision-analytic model.
Background
Incidental renal lesions are commonly encountered due to the increasing utilization of medical imaging and the increasing prevalence of renal lesions with age. Currently recommended imaging modalities to further characterize incidental indeterminate renal lesions have some inherent drawbacks. Single-phase DECT may overcome these limitations, but its cost-effectiveness remains uncertain.
Materials and methods
A decision-analytic (Markov) model was constructed to estimate life expectancy and lifetime costs for otherwise healthy 64-year-old patients with small (≤ 4 cm) incidentally detected, indeterminate renal lesions on routine imaging (e.g., ultrasound or single-phase CT). Three strategies for evaluating renal lesions for enhancement were compared: multiphase SECT (e.g., true unenhanced and nephrographic phase), multiphasic MRI, and single-phase DECT (nephrographic phase in dual-energy mode). The model incorporated modality-specific diagnostic test performance, incidence, and prevalence of incidental renal cell carcinomas (RCCs), effectiveness, costs, and health outcomes. An incremental cost-effectiveness analysis was performed to identify strategy preference at willingness-to-pay (WTP) thresholds of $50,000 and $100,000 per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analysis were performed.
Results
In the base case analysis, expected mean costs per patient undergoing characterization of incidental renal lesions were $2567 for single-phase DECT, $3290 for multiphasic CT, and $3751 for multiphasic MRI. Associated quality-adjusted life-years were the highest for single-phase DECT at 0.962, for multiphasic MRI it was 0.940, and was the lowest for multiphasic CT at 0.925. Because of lower associated costs and higher effectiveness, the single-phase DECT strategy dominated the other two strategies.
Conclusions
Single-phase DECT is potentially more cost-effective than multiphasic SECT and MRI for evaluating small incidentally detected indeterminate renal lesions.
Similar content being viewed by others
References
Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010;7(10):754-73.
Herts BR, Silverman SG, Hindman NM, et al. Management of the Incidental Renal Mass on CT: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2018;15(2):264-73
Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol. 2003;58(8):626-9.
Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology. 2008;249(1):16-31.
Silverman SG, Israel GM, Trinh QD. Incompletely characterized incidental renal masses: emerging data support conservative management. Radiology. 2015;275(1):28-42
Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398-406.
Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-30.
Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100(4):738-45.
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75(1):74-84.
Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236(2):441-50.
Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol. 2017;198(3):520-9.
Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med. 2010;362(7):624-34.
Mileto A, Nelson RC, Samei E, et al. Impact of dual-energy multi-detector row CT with virtual monochromatic imaging on renal cyst pseudoenhancement: in vitro and in vivo study. Radiology. 2014;272(3):767-76.
Tappouni R, Kissane J, Sarwani N, Lehman EB. Pseudoenhancement of renal cysts: influence of lesion size, lesion location, slice thickness, and number of MDCT detectors. AJR Am J Roentgenol. 2012;198(1):133-7.
Birnbaum BA, Hindman N, Lee J, Babb JS. Multi-detector row CT attenuation measurements: assessment of intra- and interscanner variability with an anthropomorphic body CT phantom. Radiology. 2007;242(1):109-19.
Mileto A, Barina A, Marin D, et al. Virtual Monochromatic Images from Dual-Energy Multidetector CT: Variance in CT Numbers from the Same Lesion between Single-Source Projection-based and Dual-Source Image-based Implementations. Radiology. 2016;279(1):269-77.
Solomon J, Mileto A, Nelson RC, Roy Choudhury K, Samei E. Quantitative Features of Liver Lesions, Lung Nodules, and Renal Stones at Multi-Detector Row CT Examinations: Dependency on Radiation Dose and Reconstruction Algorithm. Radiology. 2016;279(1):185-94.
Bosniak MA. The small (less than or equal to 3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies. Radiology. 1991;179(2):307-17.
Graser A, Becker CR, Staehler M, et al. Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. Invest Radiol. 2010;45(7):399-405.
Silverman SG, Mortele KJ, Tuncali K, Jinzaki M, Cibas ES. Hyperattenuating renal masses: etiologies, pathogenesis, and imaging evaluation. Radiographics. 2007;27(4):1131-43.
Hecht EM, Israel GM, Krinsky GA, et al. Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging. Radiology. 2004;232(2):373-8.
Katsuda T, Kuroda C, Fujita M. Reducing misregistration of mask image in hepatic DSA. Radiol Technol. 1997;68(6):487-90.
Ascenti G, Mazziotti S, Mileto A, et al. Dual-source dual-energy CT evaluation of complex cystic renal masses. AJR Am J Roentgenol. 2012;199(5):1026-34.
Kaza RK, Caoili EM, Cohan RH, Platt JF. Distinguishing enhancing from nonenhancing renal lesions with fast kilovoltage-switching dual-energy CT. AJR Am J Roentgenol. 2011;197(6):1375-81.
Marin D, Davis D, Roy Choudhury K, et al. Characterization of Small Focal Renal Lesions: Diagnostic Accuracy with Single-Phase Contrast-enhanced Dual-Energy CT with Material Attenuation Analysis Compared with Conventional Attenuation Measurements. Radiology. 2017;284(3):737-47.
Patel BN, Alexander L, Allen B, et al. Dual-energy CT workflow: multi-institutional consensus on standardization of abdominopelvic MDCT protocols. Abdom Radiol (NY). 2016.
Patel BN, Bibbey A, Choudhury KR, Leder RA, Nelson RC, Marin D. Characterization of Small (< 4 cm) Focal Renal Lesions: Diagnostic Accuracy of Spectral Analysis Using Single-Phase Contrast-Enhanced Dual-Energy CT. AJR Am J Roentgenol. 2017;209(4):815-25
Jung DC, Oh YT, Kim MD, Park M. Usefulness of the virtual monochromatic image in dual-energy spectral CT for decreasing renal cyst pseudoenhancement: a phantom study. AJR Am J Roentgenol. 2012;199(6):1316-9.
Marin D, Boll DT, Mileto A, Nelson RC. State of the art: dual-energy CT of the abdomen. Radiology. 2014;271(2):327-42.
Matsumoto K, Jinzaki M, Tanami Y, Ueno A, Yamada M, Kuribayashi S. Virtual monochromatic spectral imaging with fast kilovoltage switching: improved image quality as compared with that obtained with conventional 120-kVp CT. Radiology. 2011;259(1):257-62.
Yu L, Christner JA, Leng S, Wang J, Fletcher JG, McCollough CH. Virtual monochromatic imaging in dual-source dual-energy CT: radiation dose and image quality. Med Phys. 2011;38(12):6371-9.
Patel BN, Vernuccio F, Meyer M, et al. Dual-Energy CT Material Density Iodine Quantification for Distinguishing Vascular From Nonvascular Renal Lesions: Normalization Reduces Intermanufacturer Threshold Variability. AJR Am J Roentgenol. 2019;212(2):366-76.
Chandarana H, Megibow AJ, Cohen BA, et al. Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. AJR Am J Roentgenol. 2011;196(6):W693-700.
Mileto A, Marin D, Alfaro-Cordoba M, et al. Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: a multireader diagnostic performance study. Radiology. 2014;273(3):813-20.
Zarzour JG, Milner D, Valentin R, et al. Quantitative iodine content threshold for discrimination of renal cell carcinomas using rapid kV-switching dual-energy CT. Abdom Radiol (NY). 2017;42(3):727-34.
Bellini D, Panvini N, Laghi A, et al. Systematic Review and Meta-Analysis Investigating the Diagnostic Yield of Dual-Energy CT for Renal Mass Assessment. AJR Am J Roentgenol. 2019:1-10.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-8.
Health UDo, Services H. Cost-effectiveness in health and medicine: Report to the US Public Health Service by the Panel on cost-effectiveness in health and medicine. Cost-effectiveness in health and medicine: report to the US Public Health Service by the Panel on Cost-Effectiveness in Health and Medicine: US Department of Health and Human Services, 1996.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093-103.
Kang SK, Huang WC, Pandharipande PV, Chandarana H. Solid renal masses: what the numbers tell us. AJR Am J Roentgenol. 2014;202(6):1196-206.
Heilbrun ME, Remer EM, Casalino DD, et al. ACR Appropriateness Criteria indeterminate renal mass. J Am Coll Radiol. 2015;12(4):333-41.
Sun M, Abdollah F, Bianchi M, et al. Treatment management of small renal masses in the 21st century: a paradigm shift. Ann Surg Oncol. 2012;19(7):2380-7.
Pandharipande PV, Gervais DA, Hartman RI, et al. Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis. Radiology. 2010;256(3):836-46.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-38.
SEER Incidence Data, 1975-2016. November 2018 ed: National Cancer Institute.
Halpern EF, Pandharipande PV. Behind the Numbers: Sensitivity Analysis in Cost-Effectiveness Modeling. Radiology. 2017;284(2):310-2.
Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377-401.
Ho VB, Allen SF, Hood MN, Choyke PL. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology. 2002;224(3):695-700.
Taouli B, Thakur RK, Mannelli L, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology. 2009;251(2):398-407.
Klinghoffer Z, Tarride JE, Novara G, et al. Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. Can Urol Assoc J. 2013;7(3-4):108-13.
Faubel S, Patel NU, Lockhart ME, Cadnapaphornchai MA. Renal relevant radiology: use of ultrasonography in patients with AKI. Clin J Am Soc Nephrol. 2014;9(2):382-94.
Vogelzang NJ, Pal SK, Ghate SR, et al. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. J Manag Care Spec Pharm. 2018;24(6):525-33.
Corwin MT, Hansra SS, Loehfelm TW, Lamba R, Fananapazir G. Prevalence of Solid Tumors in Incidentally Detected Homogeneous Renal Masses Measuring > 20 HU on Portal Venous Phase CT. AJR Am J Roentgenol. 2018;211(3):W173-W7.
Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study. Clin Genitourin Cancer. 2019;17(1):46-57 e5.
Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59(1):135-41.
Pandharipande PV, Gervais DA, Mueller PR, Hur C, Gazelle GS. Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology. 2008;248(1):169-78.
Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health. 2010;13(1):55-60.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
BNP—research support (GE and Siemens), speaker’s bureau (GE). AB & GM—employees of Siemens. DM, RJ, BC, PP, and AK—no relevant disclosures. DaM—research support (Siemens).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Patel, B.N., Boltyenkov, A.T., Martinez, M.G. et al. Cost-effectiveness of dual-energy CT versus multiphasic single-energy CT and MRI for characterization of incidental indeterminate renal lesions. Abdom Radiol 45, 1896–1906 (2020). https://doi.org/10.1007/s00261-019-02380-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-019-02380-x